Cardlytics, Inc. (NASDAQ:CDLX) Given Consensus Rating of “Reduce” by Brokerages

Cardlytics, Inc. (NASDAQ:CDLX) has earned a consensus recommendation of “Reduce” from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and six have issued a hold rating on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $6.92.

A number of research analysts recently commented on CDLX shares. Lake Street Capital lowered shares of Cardlytics from a “buy” rating to a “hold” rating and decreased their price target for the company from $18.00 to $5.00 in a research note on Thursday, August 8th. Needham & Company LLC downgraded Cardlytics from a “buy” rating to a “hold” rating in a research report on Thursday, August 8th. Craig Hallum cut Cardlytics from a “buy” rating to a “hold” rating in a report on Thursday, August 8th. Northland Capmk lowered Cardlytics from a “strong-buy” rating to a “hold” rating in a report on Friday, August 16th. Finally, Bank of America downgraded Cardlytics from a “neutral” rating to an “underperform” rating and dropped their target price for the stock from $4.00 to $3.50 in a report on Thursday, August 15th.

Insider Buying and Selling at Cardlytics

In other news, COO Amit Gupta sold 22,699 shares of the stock in a transaction on Wednesday, July 24th. The stock was sold at an average price of $8.66, for a total transaction of $196,573.34. Following the sale, the chief operating officer now directly owns 150,569 shares of the company’s stock, valued at approximately $1,303,927.54. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, COO Amit Gupta sold 22,699 shares of the company’s stock in a transaction that occurred on Wednesday, July 24th. The shares were sold at an average price of $8.66, for a total transaction of $196,573.34. Following the completion of the sale, the chief operating officer now owns 150,569 shares of the company’s stock, valued at approximately $1,303,927.54. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Scott A. Hill acquired 40,000 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The stock was purchased at an average cost of $3.58 per share, for a total transaction of $143,200.00. Following the completion of the purchase, the director now directly owns 40,000 shares of the company’s stock, valued at $143,200. The disclosure for this purchase can be found here. Insiders sold 43,665 shares of company stock valued at $261,149 in the last three months. Corporate insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On Cardlytics

A number of institutional investors have recently modified their holdings of CDLX. Quadrature Capital Ltd bought a new position in Cardlytics in the first quarter valued at about $1,906,000. Vanguard Group Inc. grew its holdings in shares of Cardlytics by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 2,211,595 shares of the company’s stock valued at $32,046,000 after purchasing an additional 57,805 shares during the last quarter. Renaissance Technologies LLC increased its position in Cardlytics by 711.9% during the 2nd quarter. Renaissance Technologies LLC now owns 351,035 shares of the company’s stock worth $2,882,000 after purchasing an additional 307,800 shares in the last quarter. Susquehanna Fundamental Investments LLC lifted its stake in Cardlytics by 13.8% in the 1st quarter. Susquehanna Fundamental Investments LLC now owns 31,536 shares of the company’s stock valued at $457,000 after purchasing an additional 3,836 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Cardlytics by 15.4% in the second quarter. Bank of New York Mellon Corp now owns 135,924 shares of the company’s stock valued at $1,116,000 after buying an additional 18,179 shares in the last quarter. Institutional investors and hedge funds own 68.10% of the company’s stock.

Cardlytics Stock Performance

Shares of NASDAQ CDLX opened at $4.08 on Tuesday. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 1.01. The company has a market capitalization of $199.03 million, a P/E ratio of -0.92 and a beta of 1.67. Cardlytics has a 12 month low of $2.89 and a 12 month high of $20.52. The stock has a 50 day moving average of $3.60 and a 200-day moving average of $7.49.

Cardlytics (NASDAQ:CDLX) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.12. The firm had revenue of $69.64 million during the quarter, compared to analysts’ expectations of $75.39 million. Cardlytics had a negative net margin of 50.21% and a negative return on equity of 17.96%. The company’s revenue for the quarter was down 9.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.57) earnings per share. As a group, equities research analysts predict that Cardlytics will post -1.72 EPS for the current year.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.